Publication | Closed Access

A peptide–doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo

UrologyProstate Tumor CellsMedicinePeptide EngineeringPeptide TherapeuticPeptide SciencePeptide TherapeuticsImmunotherapeuticsProstatic DiseasePharmacologyProstate-specific Antigen